Literature DB >> 19167495

Clinical applications for estetrol.

Monique Visser1, Herjan J T Coelingh Bennink.   

Abstract

In this paper the potential clinical applications for the human fetal estrogen estetrol (E(4)) are presented based on recently obtained data in preclinical and clinical studies. In the past E(4) has been classified as a weak estrogen due to its rather low estrogen receptor affinity. However, recent research has demonstrated that due to its favorable pharmacokinetic properties, especially the slow elimination and long half-life, E(4) is an effective orally bioavailable estrogen agonist with estrogen antagonistic effects on the breast in the presence of estradiol. Based on the pharmacokinetic properties, the pharmacological profile and the safety and efficacy results in human studies, E(4) seems potentially suitable as a drug for human use in applications such as hormone replacement therapy (vaginal atrophy and vasomotor symptoms), contraception, osteoporosis and breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19167495     DOI: 10.1016/j.jsbmb.2008.12.013

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  8 in total

Review 1.  Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes.

Authors:  Hyunyoung Jeong
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-06       Impact factor: 4.481

2.  Effects of Estetrol on Migration and Invasion in T47-D Breast Cancer Cells through the Actin Cytoskeleton.

Authors:  Maria Silvia Giretti; Maria Magdalena Montt Guevara; Elena Cecchi; Paolo Mannella; Giulia Palla; Stefania Spina; Guja Bernacchi; Silvia Di Bello; Andrea Riccardo Genazzani; Alessandro D Genazzani; Tommaso Simoncini
Journal:  Front Endocrinol (Lausanne)       Date:  2014-05-26       Impact factor: 5.555

3.  Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.

Authors:  Ingrid J M Duijkers; Christine Klipping; Yvette Zimmerman; Nicole Appels; Maud Jost; Catherine Maillard; Marie Mawet; Jean-Michel Foidart; Herjan J T Coelingh Bennink
Journal:  Eur J Contracept Reprod Health Care       Date:  2015       Impact factor: 1.848

4.  Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells.

Authors:  Wei Yue; Carole Verhoeven; Herjan Coelingh Bernnink; Ji-Ping Wang; Richard J Santen
Journal:  Breast Cancer (Auckl)       Date:  2019-05-15

Review 5.  Estetrol and Mammary Gland: Friends or Foes?

Authors:  Anne Gallez; Isabelle Dias Da Silva; Vincent Wuidar; Jean-Michel Foidart; Christel Péqueux
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-08-31       Impact factor: 2.673

Review 6.  Estetrol: A New Choice for Contraception.

Authors:  Franca Fruzzetti; Tiziana Fidecicchi; Maria Magdalena Montt Guevara; Tommaso Simoncini
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

7.  The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation.

Authors:  Anne Abot; Coralie Fontaine; Mélissa Buscato; Romain Solinhac; Gilles Flouriot; Aurélie Fabre; Anne Drougard; Shyamala Rajan; Muriel Laine; Alain Milon; Isabelle Muller; Daniel Henrion; Marine Adlanmerini; Marie-Cécile Valéra; Anne Gompel; Céline Gerard; Christel Péqueux; Mélanie Mestdagt; Isabelle Raymond-Letron; Claude Knauf; François Ferriere; Philippe Valet; Pierre Gourdy; Benita S Katzenellenbogen; John A Katzenellenbogen; Françoise Lenfant; Geoffrey L Greene; Jean-Michel Foidart; Jean-François Arnal
Journal:  EMBO Mol Med       Date:  2014-10       Impact factor: 12.137

8.  Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives.

Authors:  Marie Mawet; Catherine Maillard; Christine Klipping; Yvette Zimmerman; Jean-Michel Foidart; Herjan J T Coelingh Bennink
Journal:  Eur J Contracept Reprod Health Care       Date:  2015-07-27       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.